- Protein family review
Genome Biology volume 5, Article number: 241 (2004)
Cyclooxygenases (COXs) catalyze the rate-limiting step in the production of prostaglandins, bioactive compounds involved in processes such as fever and sensitivity to pain, and are the target of aspirin-like drugs. COX genes have been cloned from coral, tunicates and vertebrates, and in all the phyla where they are found, there are two genes encoding two COX isoenzymes; it is unclear whether these genes arose from an early single duplication event or from multiple independent duplications in evolution. The intron-exon arrangement of COX genes is completely conserved in vertebrates and mostly conserved in all species. Exon boundaries largely define the four functional domains of the encoded protein: the amino-terminal hydrophobic signal peptide, the dimerization domain, the membrane-binding domain, and the catalytic domain. The catalytic domain of each enzyme contains distinct peroxidase and cyclooxygenase active sites; COXs are classified as members of the myeloperoxidase family. All COXs are homodimers and monotopic membrane proteins (inserted into only one leaflet of the membrane), and they appear to be targeted to the lumenal membrane of the endoplasmic reticulum, where they are N-glycosylated. In mammals, the two COX genes encode a constitutive isoenzyme (COX-1) and an inducible isoenzyme (COX-2); both are of significant pharmacological importance.
Gene organization and evolutionary history
Cyclooxygenases (COXs), also known as prostaglandin H synthases or prostaglandin endoperoxide synthases (E.C. 22.214.171.124), are fatty-acid oxygenases of the myeloperoxidase superfamily that are most closely related to the pathogen-inducible oxidases and linoleate diol synthases of plants and fungi . The purification of COX-1 (then called simply COX) from sheep  and bovine  seminal vesicles in 1976 led to the cloning of the COX-1 gene in 1988 [4–6]. For many years, it was thought that the constitutively active COX-1 protein was the only cyclooxygenase in eukaryotic cells, but in 1991 a second, inducible enzyme was identified through studies of cell division; this second enzyme is now called COX-2 [7, 8]. The structure of the human COX-1 and COX-2 genes are shown in Figure 1a, and the properties of COX-1 and COX-2 and the genes encoding them are compared in Table 1.
All vertebrates investigated, including cartilaginous fishes, bony fishes, birds, and mammals, have two COX genes: one encoding the constitutive COX-1 and another the inducible COX-2. COX-1 and COX-2 share approximately 60-65% amino-acid identity with each other; COX-1 orthologs (without the signal peptide) share approximately 70-95% amino-acid identity across vertebrate species and COX-2 orthologs share 70-90%. Additionally, coral (of the phylum Cnidaria) and sea squirt (ascidian) each have two COX genes, which may have arisen from gene-duplication events independent from those that produced vertebrate COX-1 and COX-2 . It is clear that the vertebrate, coral and ascidian COX genes all descend from a common ancestor.
Intron-exon junctions are highly conserved in all species, with a few notable exceptions: the vertebrate COX-1 genes contain an extra intron (intron 1), and the ascidian and coral genes have extra introns or lack some exons in the regions that encode exons 6, 7 or 11 in vertebrate COX-1 . The exon structures of COX genes largely reflect the domains encoded by the proteins (Figure 1b). The structure of human cyclooxygenase genes and their expression and regulation have been reviewed elsewhere .
COX genes have not been found in insects, unicellular organisms, or plants, although prostaglandins, their products, have been found in some of these organisms . Recently, an enzyme that catalyzes the synthesis of prostaglandin E2 from arachidonic acid (the substrate of COXs) was cloned from the protozoan Entamoeba histolytica. This enzyme shows no clear structural similarity to COXs, suggesting that alternative evolutionary paths to prostaglandin synthesis have evolved in some organisms .
Characteristic structural features
COXs are all close to 600 amino acids in size and have a similar primary structure [13, 14] (Figure 1b). The crystal structure of sheep COX-1 (minus the post-translationally cleaved signal peptide), was obtained in 1994 ; human and mouse COXs have since been crystallized and show strikingly similar features [16, 17]. After the signal peptide, the amino terminus of the protein contains a single epidermal growth factor (EGF) module with conserved disulfide bonds that functions as a dimerization domain. This is followed by a series of four amphipathic helices that anchors the protein to one leaflet of the membrane. This 'monotopic' type of insertion into a membrane has been found only in this enzyme and a few other proteins such as squalene cyclase and S-mandelate dehydrogenase [18, 19]. The remainder of the protein consists of the catalytic domain, which has two distinct cyclooxygenase and peroxidase active sites.
COXs are highly conserved, and few significant differences are seen in the dimerization, membrane-binding and catalytic domains between COXs from different species. The amino-terminal hydrophobic signal peptides differ significantly in length between species. In the case of two splice variants of canine COX-1, the signal peptide has been found not to be cleaved from the enzyme when expressed in insect cells .
The catalytic domain contains conserved alpha-helical structures and a heme-binding motif shared with other peroxidases . COXs are glycosylated on asparagine in all organisms. One N-glycosylation site (Asn143, using the numbering of human COX-1) is absolutely conserved, and other sites are shifted only slightly in different homologs. For example, Asn410 in sheep COX-1 (orthologous to Asn4O9 in human COX-1), found to be essential for folding , is shifted to Asn394 in coral COXs. The cyclooxygenase active site is a narrow tunnel, approximately 8 Å wide and 25 Å long, that opens in the membrane-binding domain (Figure 2). This site accepts the arachidonic acid that is liberated from the membrane by cellular phospholipases. Amino acids lining this site are largely hydrophobic and serve to 'solvate' the hydrophobic substrate into the site . Exceptions to this hydrophobicity are Arg119, Tyr384 and Ser529 (numbered according to the human COX-1 enzyme sequence). Arg119 coordinates the carboxyl group of arachidonic acid by a salt bridge or hydrogen bond; Ser529 coordinates the geometry of attack in the complex bis-dioxygenation reaction performed; and Tyr384 forms a critical tyrosyl radical that initiates the cyclooxygenase reaction by abstraction of hydrogen from arachidonic acid (see Mechanism section). Non-steroidal anti-inflammatory drugs (NSAIDs) competitively inhibit the cyclooxygenase active site; an exception is the NSAID aspirin, which covalently modifies the enzyme by acetylating Ser529. In contrast to the cyclooxygenase active site, the peroxidase site is a solvent accessible cleft located on the surface of the enzyme furthest from the membrane (Figure 2).
Localization and function
COX-1 is ubiquitously and constitutively expressed in mammalian tissues and cells, whereas COX-2 is highly inducible and is generally present in mammalian tissues at very low levels, unless increased by one of many types of stimuli such as cytokines and growth factors.
Both COXs are largely located on the lumenal side of the endoplasmic reticulum (ER) membrane and the nuclear envelope, although they have also been detected in some situations in lipid bodies, mitochondria, filamentous structures, vesicles and in the nucleus [23–26]. The lumen of the ER is important for both the structure and function of COXs: its oxidative potential allows formation of the disulfide bonds of the enzymes, and N-linked glycosylation - which occurs in the ER - appears to be necessary for proper protein folding . Moreover, the final product of COXs, prostaglandin H2, is sufficiently non-polar to diffuse through the membrane of the ER to isomerases located on the cytosolic surface of the ER or in the cytosol (Figures 2, 3). Lipid bodies may provide a similar environment, but the role of COXs in the nucleus is unknown.
Both classes of COX are bifunctional enzymes with two distinct catalytic activities: cyclooxygenase (or bis-dioxygenase) activity and peroxidase activity (Figure 3a). The primary products of COXs were first detected in human seminal fluid by clinicians studying uterine contraction . Thought to be the product of the prostate gland, these highly potent bioactive compounds were given the name prostaglandins. They are synthesized in virtually all tissues in vertebrates, however, and some organisms that lack prostate glands, such as corals, also synthesize prostaglandins. Thus, in many respects the term prostaglandin is a misnomer. Initially, the enzyme activity that synthesized prostaglandins was frequently called prostaglandin synthetase, but because it does not require ATP it is now called prostaglandin G/H synthase to fit the nomenclature convention. It is more popularly known as cyclooxygenase, a name that only partially describes the enzyme since it refers to only one of its two enzymatic activities.
Prostaglandin isomers - including thromboxane and prostaglandins D2, E2, F2α, and I2 (prostacyclin; Figure 3b) - function in numerous physiological and pathophysiological processes, such as pyresis (fever), algesia (sensitivity to pain), inflammation, thrombosis, parturition, mitogenesis, vasodilation and vasoconstriction, ovulation, and renal function. Prostaglandin isomers act upon G-protein-coupled receptors , and there are multiple receptors for some isoforms (such as prostaglandin E2). Prostaglandins are short-lived in vivo (with half-lives of seconds to minutes), and act in an autocrine or a paracrine rather than an endocrine fashion. COX-1 was first studied in tissue and cell homogenates, and in this context was shown by Vane  to be the inhibitory target of NSAIDs.
The cyclooxygenase activity of COXs oxygenates arachidonic acid to produce prostaglandin G2, a cyclopentane hydroperoxy endoperoxide; the peroxidase activity of COXs then reduces this to prostaglandin H2 (Figure 3a). The two reactions are functionally interconnected (see below and Figure 3c). A branch-chain reaction mechanism for COX, indicating that the two reaction cycles are coupled, was first proposed by Ruf and colleagues . The mechanism by which arachidonic acid is converted to prostaglandin H2 has been the subject of excellent reviews [31, 32]. The newly synthesized COX enzyme needs to be activated at Tyr384 (in human COX-1; Tyr371 in human COX-2) to produce a tyrosyl radical; this activation involves the heme in the peroxidase site (see Figure 3b). The tyrosyl radical converts arachidonic acid to an arachidonyl radical, which reacts with two molecules of oxygen to yield prostaglandin G2 This then diffuses to the peroxidase site and is reduced to prostaglandin H2 by the peroxidase activity. The cyclooxygenase activity is dependent on heme oxidation - that is, on the peroxidase activity - but continuous peroxidase activity is not necessary for cyclooxygenase activity, as the tyrosyl radical is regenerated in each catalytic cycle (Figure 3c). Prostaglandin H2 is the root prostaglandin from which prostaglandin isomers such as thromboxane and prostacyclin are made by downstream synthases, via isomerization and oxidation or reduction reactions (Figure 3b). Cyclooxygenases have short catalytic life spans (frequently 1-2 minutes at Vmax in vitro) because the enzyme is autoinactivated. The mechanism of autoinactivation is unknown, but reactive tyrosyl radicals may cause internal protein modification.
The exact distinct functions of COX-1 and COX-2 are still being unraveled . There is increasing evidence for the involvement of COXs in the development and progression of cancer, Alzheimer's disease and other pathophysiological states. Development of therapeutic and diagnostic tools to treat these diseases is being actively investigated. Moreover, variants of cyclooxygenase derived from alternative splicing have been reported (reviewed in [13, 34]). Elucidation of the roles played by these variants could provide greater insight into the roles of COXs in physiology and disease.
Daiyasu H, Toh H: Molecular evolution of the myeloperoxidase family. J Mol Evol. 2000, 51: 433-445. An evolutionary analysis of the myeloperoxidases
Hemler M, Lands WEM, Smith WL: Purification of the cyclooxygenase that forms prostaglandins: demonstration of two forms of iron in the holoenzyme. J Biol Chem. 1976, 251: 5575-5579. The first isolation and purification of cyclooxygenase from sheep seminal vesicles
Miyamoto T, Ogino N, Yamamoto S, Hayaishi O: Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem. 1976, 251: 2629-2636. The first isolation and purification of cyclooxygenase enzyme from bovine seminal vesicles
Yokoyama C, Tanabe T: Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun. 1989, 165: 888-894. The cloning of human cyclooxygenase-1 (COX-1)
Merlie JP, Fagan D, Mudd J, Needleman P: Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem. 1988, 263: 3550-3553. The cloning of the first cyclooxygenase gene from sheep
DeWitt DL, Smith WL: Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA. 1988, 85: 1412-1416. The cloning of the first cyclooxygenase gene from sheep
Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991, 88: 2692-2696. The first report on the cloning and characterization of a second isozyme of cyclooxygenase (COX-2)
Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991, 266: 12866-12872. Cloning and characterization of a second isozyme of cyclooxygenase (COX-2)
Jarving R, Jarving I, Kurg R, Brash AR, Samel N: On the evolutionary origin of cyclooxygenase (COX) isozymes: characterization of marine invertebrate COX genes points to independent duplication events in vertebrate and invertebrate lineages. J Biol Chem. 2004, 279: 13624-13633. 10.1074/jbc.M313258200. An evolutionary analysis of invertebrate cyclooxygenases
Tanabe T, Tohnai N: Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002, 68-69: 95-114. 10.1016/S0090-6980(02)00024-2. A review on the gene structures and expression of COX-1 and COX-2
Bundy GL: Nonmammalian sources of eicosanoids. Adv Prostaglandin Thromboxane Leukot Res. 1985, 14: 229-262. A review on prostaglandins from nonmammalian sources
Dey I, Keller K, Belley A, Chadee K: Identification and characterization of a cyclooxygenase-like enzyme from Entamoeba histolytica. Proc Natl Acad Sci USA. 2003, 100: 13561-13566. 10.1073/pnas.1835863100. The cloning of a prostaglandin-producing enzyme unrelated to the cyclooxygenases
Simmons DL, Botting RM, Hla T: Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. A review on the biology of prostaglandin synthesis and inhibition by non-steroidal anti-inflammatory drugs (NSAIDs)
Garavito RM, Malkowski MG, DeWitt DL: The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 2002, 68-69: 129-152. 10.1016/S0090-6980(02)00026-6. A review on the structure of cyclooxygenases
Picot D, Loll P, Garavito M: The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994, 367: 243-249. 10.1038/367243a0. A landmark study elucidating the three dimensional structure of sheep COX-1
Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF: Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol. 1996, 3: 927-933. 10.1038/nsb1196-927. The first report on the crystal structure of human COX-2
Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, et al: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996, 384: 644-648. 10.1038/384644a0. The crystal structure of murine COX-2
Wendt KU, Poralla K, Schulz GE: Structure and function of a squalene cyclase. Science. 1997, 277: 1811-1815. 10.1126/science.277.5333.1811. Describes the crystal structure of squalene cyclase, which has membrane-binding properties similar to those of cyclooxygenase
Sukumar N, Xu Y, Gatti DL, Mitra B, Mathews FS: Structure of an active soluble mutant of the membrane-associated (S)-mandelate dehydrogenase. Biochemistry. 2001, 40: 9870-9878. 10.1021/bi010938k. Describes the crystal structure of S-mandelate dehydrogenase, which has membrane-binding properties similar to those of cyclooxygenase
Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 2002, 99: 13926-13931. 10.1073/pnas.162468699. The cloning and characterization of canine COX-1 variants
Otto JC, DeWitt DL, Smith WL: N-glycosylation of prostaglandin endoperoxide synthase-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem. 1993, 268: 18234-18242. Describes the role of glycosylation in cyclooxygenases
Thuresson ED, Lakkides KM, Rieke CJ, Sun Y, Wingerd BA, Micielli R, Mulichack AM, Malkowski MG, Garavito RM, Smith WL: Prostaglandin endoperoxide H synthase-1: the function of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J Biol Chem. 2001, 276: 10347-10358. 10.1074/jbc.M009377200. A mutational analysis of the cyclooxygenase active site
Bozza PT, Yu W, Penrose JF, Morgan ES, Dvorak AM, Weller PF: Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med. 1997, 186: 909-920. 10.1084/jem.186.6.909. Cyclooxygenases in lipid bodies
Liou JY, Deng WG, Gilroy DW, Shyue SK, Wu KK: Colocalization and interaction of cyclooxygenase-1 with caveolin-1 in human fibroblasts. J Biol Chem. 2001, 276: 34975-34982. 10.1074/jbc.M105946200. Cyclooxygenases in vesicles
Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chimery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD: Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA. 1997, 94: 657-662. 10.1073/pnas.94.2.657. The nuclear localization of COX-2
Liou JY, Shyue SK, Tsai MJ, Chung CL, Chu KY, Wu KK: Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells. J Biol Chem. 2000, 275: 15314-15320. 10.1074/jbc.275.20.15314. Demonstration of the colocalization of cyclooxygenase with filamentous structures
Goldblatt MW: A depressor substance in seminal fluid. J Soc Chem Ind. 1933, 52: 1056-1057. The first detection of the products of COXs in human seminal fluid
Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures properties and functions. Physiol Rev. 1999, 79: 1193-1226. A review on prostanoid receptors
Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971, 231: 232-235. The first report indicating that the target for aspirin-like drugs is cyclooxygenase
Dietz R, Nastainczyk W, Ruf HH: Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2. Eur J Biochem. 1988, 171: 321-328. The first paper to propose a branch chain mechanism for cyclooxygenase catalysis
Rouzer CA, Marnett LJ: Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases. Chem Rev. 2003, 103: 2239-2304. 10.1021/cr000068x. A review on the reaction mechanism of cyclooxygenase
van der Donk WA, Tsai A-L, Kulmacz RJ: The cyclooxygenase reaction mechanism. Biochemistry. 2002, 41: 15451-15457. 10.1021/bi026938h. A review on the reaction mechanism of cyclooxygenase
Loftin CD, Tiano HF, Langenbach R: Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002, 68-69: 177-185. 10.1016/S0090-6980(02)00028-X. Determination of the roles of COX-1 and COX-2 using COX-1-/-, COX-2-/-, and COX-1-/- COX-2-/- mice
Simmons DL: Variants of cyclooxygenase-1 and their roles in medicine. Thrombosis Res. 2003, 110: 265-268. 10.1016/S0049-3848(03)00380-3. A review on variants of COX-1
Smith WL, De Witt DL, Garavito RM: Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem. 2000, 69: 145-182. 10.1146/annurev.biochem.69.1.145. A review on cyclooxygenases
This work was supported by National Institute of Health grant AR 46688 and Merck, USA. We wish to thank K.L.T. Roos, D. Melville and C. Gurney for helping us in numerous ways.
About this article
Cite this article
Chandrasekharan, N., Simmons, D.L. The cyclooxygenases. Genome Biol 5, 241 (2004). https://doi.org/10.1186/gb-2004-5-9-241
- Arachidonic Acid
- Cyclooxygenase Activity
- Tyrosyl Radical